Search filters

List of works by Michael Willis

A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus

scientific article published on 20 October 2015

A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus

scientific article

A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden

scientific article published on 29 July 2009

Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review

scientific article published on 24 August 2019

Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM

scientific article published on 13 May 2020

Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge

article

Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting.

scientific article published on 18 April 2013

Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors

scientific article published on 11 January 2019

Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States

scientific article published on 6 February 2018

Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico

scientific article published on 03 June 2015

Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada

scientific article published on 15 July 2016

Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection

scientific article

Is Canagliflozin Cost-Effective Compared to Sitagliptin Across Multiple Lines of Type 2 Diabetes Mellitus (T2dm) Therapy In Ireland?

scientific article published on 26 October 2014

Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India

scientific article published on 28 November 2018

Multivariate Prediction Equations for HbA1c Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modeling.

scientific article

Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden

scientific article published on January 2010

The Cost-Effectiveness OF Canagliflozin (Cana) Versus Dapagliflozin (Dapa) In Patients With Type 2 Diabetes Mellitus (T2dm) With Inadequate Control On Metformin (Met) Monotherapy In The United Kingdom

scientific article published on 26 October 2014

The Cost-Effectiveness Of Canagliflozin Verse Liraglutide In Patients With Type 2 Diabetes (T2dm) Failing To Achieve Glycaemic Control On Metformin Monotherapy In Ireland

scientific article published on 26 October 2014

The Cost-Effectiveness of Canagliflozin Verse Insulin-Secretagogues (Sulphonylureas) or Insulin In Patients With Type 2 Diabetes Mellitus (T2dm) As An Add-On To Metformin In Ireland

scientific article published on 26 October 2014

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden

scientific article published on 19 January 2010

Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM).

scientific article

Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM).

scientific article published on 12 November 2016

Validation of the IHE Cohort Model of Type 2 Diabetes and the impact of choice of macrovascular risk equations

scientific article

Paulina is supported by:

About Paulina

Help